FindTrial
Sign In

JNJ-79635322

DRUG7 trials

Sponsors

European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale, Universitaetsklinikum Heidelberg AöR, Janssen Research & Development, LLC, University of Heidelberg Medical Center

Conditions

Multiple MyelomaNewly Diagnosed Multiple Myeloma in patients eligible for stem cell transplantationPreviously Treated Amyloid Light-chain (AL) AmyloidosisRelapsed or Refractory Multiple Myeloma

Phase 1

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RecruitingNCT05652335
Janssen Research & Development, LLCPreviously Treated Amyloid Light-chain (AL) Amyloidosis, Relapsed or Refractory Multiple Myeloma
Start: 2022-11-22End: 2028-08-07Target: 180Updated: 2026-03-13
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
RecruitingNCT06768489
Janssen Research & Development, LLCMultiple Myeloma
Start: 2024-12-04End: 2028-11-23Target: 140Updated: 2026-03-13

Phase 2

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
RecruitingNCT05695508
University of Heidelberg Medical CenterMultiple Myeloma
Start: 2022-12-01End: 2029-09-15Target: 160Updated: 2025-12-24
A Phase 2, Multi-cohort Study Applying Innovative MRD Techniques for Transplant Eligible Participants with Previously Untreated Multiple Myeloma - TAURUS
RecruitingCTIS2023-505221-14-00
European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa SocialeMultiple Myeloma
Start: 2023-12-04Target: 237Updated: 2026-01-26
A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-,Talquetamab- and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma
RecruitingCTIS2024-517382-17-00
Universitaetsklinikum Heidelberg AöRNewly Diagnosed Multiple Myeloma in patients eligible for stem cell transplantation
Start: 2022-11-30Target: 130Updated: 2025-08-19
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingNCT07266441
Janssen Research & Development, LLCMultiple Myeloma
Start: 2026-02-08End: 2028-12-12Target: 157Updated: 2026-03-13

Phase 3

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingNCT07258511
Janssen Research & Development, LLCMultiple Myeloma
Start: 2026-02-04End: 2031-09-30Target: 400Updated: 2026-03-19

Related Papers

Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy
Blood2025-11-03
Clinical pharmacology strategies to support dose optimization of the recommended Phase 2 dose regimen of JNJ-5322, a BCMA×GPRC5D×CD3 trispecific antibody, in Relapsed/Refractory multiple myeloma
Blood2025-11-03
Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma
Blood2025-11-03
Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.
2025-10-16
First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results.
Journal of Clinical Oncology2025-05-2821 citations
Characterization of JNJ-79635322, a Novel BCMAxGPRC5DxCD3 T-Cell Redirecting Trispecific Antibody, for the Treatment of Multiple Myeloma
Blood2023-11-0222 citations